Loading company…
Pacylex Pharmaceuticals develops cancer treatments, including the oral drug candidate zelenirstat.
Founded in 2012 and based in Edmonton, Canada, Pacylex Pharmaceuticals develops therapies for refractory cancers. Its lead candidate, zelenirstat, is an oral myristoylation inhibitor being developed for solid tumors and blood cancers. The company was founded by John Mackey, Luc Berthiaume and Ryan Heit; Michael Weickert is CEO. In June 2021, Pacylex raised USD 3.90 mn in venture debt to support an initial Phase 1 investigation of PCLX-001.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in